Skip to main content
. 2005 Jan 14;102(5):1578–1583. doi: 10.1073/pnas.0406808102

Fig. 1.

Fig. 1.

The LC antagonist F991 inhibits antigen-induced early-phase bronchoconstriction and mast cell activation found after intra-airway DNBS challenge of mice actively immunized with DNFB. (a) DNFB- (black circle) but not vehicle- (open circle) immunized mice showed an acute bronchoconstrictive response after challenge. Intranasal application of F991 (200 μg per mouse) 30 min before challenge (black triangle) resulted in a profound reduction of bronchoconstriction in DNFB-immunized mice. Intranasal application of F991 did not influence Penh values of vehicle-immunized mice (open triangle); n = 5–6; *, P < 0.05, for the whole curve. (b) mMCP-1 levels in serum of DNFB-immunized mice (black bars) are enhanced compared with vehicle-immunized (open bars) mice 30 min after challenge. Intranasal application of F991 resulted in inhibition of DNBS-induced increase in mMCP-1 serum levels of DNFB-immunized mice; n = 6; *, P < 0.05.